Arthritogenic T cell epitope in glucose-6-phosphate isomerase-induced arthritis by Iwanami, Keiichi et al.
Open Access
Available online http://arthritis-research.com/content/10/6/R130
Page 1 of 12
(page number not for citation purposes)
Vol 10 No 6 Research article
Arthritogenic T cell epitope in glucose-6-phosphate 
isomerase-induced arthritis
Keiichi Iwanami1, Isao Matsumoto2, Yoko Tanaka1, Asuka Inoue1, Daisuke Goto1, Satoshi Ito1, 
Akito Tsutsumi1 and Takayuki Sumida1
1Department of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Science, University of 
Tsukuba, 1-1-1 Tennoudai, Tsukuba 305-8575, Japan
2PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
Corresponding author: Isao Matsumoto, ismatsu@md.tsukuba.ac.jp
Received: 25 Jul 2008 Revisions requested: 22 Sep 2008 Revisions received: 27 Sep 2008 Accepted: 7 Nov 2008 Published: 7 Nov 2008
Arthritis Research & Therapy 2008, 10:R130 (doi:10.1186/ar2545)
This article is online at: http://arthritis-research.com/content/10/6/R130
© 2008 Matsumoto et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Arthritis induced by immunisation with glucose-6-
phosphate isomerase (GPI) in DBA/1 mice was proven to be T
helper (Th) 17 dependent. We undertook this study to identify
GPI-specific T cell epitopes in DBA/1 mice (H-2q) and
investigate the mechanisms of arthritis generation.
Methods For epitope mapping, the binding motif of the major
histocompatibility complex (MHC) class II (I-Aq) from DBA/1
mice was identified from the amino acid sequence of T cell
epitopes and candidate peptides of T cell epitopes in GPI-
induced arthritis were synthesised. Human GPI-primed CD4+ T
cells and antigen-presenting cells (APCs) were co-cultured with
each synthetic peptide and the cytokine production was
measured by ELISA to identify the major epitopes. Synthetic
peptides were immunised in DBA/1 mice to investigate whether
arthritis could be induced by peptides. After immunisation with
the major epitope, anti-interleukin (IL) 17 monoclonal antibody
(mAb) was injected to monitor arthritis score. To investigate the
mechanisms of arthritis induced by a major epitope, cross-
reactivity to mouse GPI peptide was analysed by flow cytometry
and anti-GPI antibodies were measured by ELISA. Deposition of
anti-GPI antibodies on the cartilage surface was detected by
immunohistology.
Results We selected 32 types of peptides as core sequences
from the human GPI 558 amino acid sequence, which binds the
binding motif, and synthesised 25 kinds of 20-mer peptides for
screening, each containing the core sequence at its centre. By
epitope mapping, human GPI325–339 was found to induce
interferon (IFN) γ and IL-17 production most prominently.
Immunisation with human GPI325–339 could induce
polyarthritis similar to arthritis induced by human GPI protein,
and administration of anti-IL-17 mAb significantly ameliorated
arthritis (p < 0.01). Th17 cells primed with human GPI325–339
cross-reacted with mouse GPI325–339, and led B cells to
produce anti-mouse GPI antibodies, which were deposited on
cartilage surface.
Conclusions Human GPI325–339 was identified as a major
epitope in GPI-induced arthritis, and proved to have the
potential to induce polyarthritis. Understanding the pathological
mechanism of arthritis induced by an immune reaction to a
single short peptide could help elucidate the pathogenic
mechanisms of autoimmune arthritis.
Introduction
Rheumatoid arthritis (RA) is characterised by symmetrical pol-
yarthritis and joint destruction. Although the aetiology is con-
sidered to be autoimmune reactivity to some antigens, the
exact mechanisms are not fully understood. So far, several
models of arthritis have been described and analysed to
understand the aetiological mechanisms of RA. Glucose-6-
phosphate isomerase (GPI)-induced arthritis, a murine model
of RA, is induced by immunisation with recombinant human
(rh) GPI of DBA/1 mice [1]. We have previously demonstrated
APC: antigen-presenting cell; CIA: collagen-induced arthritis; CII: type II collagen; CTLA-4 Ig: cytotoxic T-lymphocyte antigen 4 immunoglobulin; 
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that the T helper (Th) 17 subset of CD4+ T cells play a central
role in the pathogenesis of GPI-induced arthritis; GPI-specific
CD4+ T cells were skewed to Th17 at the time of onset, and
blockade of interleukin (IL) 17 resulted in a significant amelio-
ration of arthritis [2]. Furthermore, the data that the administra-
tion of cytotoxic T-lymphocyte antigen 4 immunoglobulin
(CTLA-4 Ig) in the effector phase ameliorated the progress of
arthritis implies the importance of Th17 cells even in the effec-
tor phase [3].
In this study, we further explored the epitopes of GPI-specific
CD4+ T cells and identified human GPI (hGPI)325–339 as a
major epitope. Interestingly, the amino acid sequence of
hGPI325–339 (IWYINCFGCETHAML) was the same as that of
bovine (type II collagen) CII256–270(GEPGIAGFKGEQGPK),
the dominant epitope of collagen-induced arthritis (CIA), at the
major histocompatibility complex (MHC) binding sites [4]. Of
note is that arthritis similar to GPI-induced arthritis was gener-
ated by immunisation with a short 15-mer single peptide in
genetically unaltered mice. By analysis of peptide-induced
arthritis, we found that hGPI325–339-primed Th17 cells reacted
with mouse GPI (mGPI)325–339 peptide and subsequently lead
to the production of anti-mouse GPI antibodies, which depos-
ited over the cartilage surface of inflaming joints. Our findings
should be helpful in unravelling the mechanism of autoimmune
arthritis.
Materials and methods
Mice
DBA/1 mice were purchased from Charles River Laboratories,
Japan. All mice were kept under specific pathogen-free condi-
tions and all experiments were conducted in accordance with
the University of Tsukuba ethical guidelines.
GPI and synthetic peptides
Recombinant mouse GPI and rhGPI were prepared as
described previously [5,6]. Briefly, human GPI or mouse GPI
cDNA was inserted into the plasmid pGEX-4T3 (Pharmacia,
Uppsala, Sweden) for expression of glutathione S-transferase-
tagged proteins. Escherichia coli harboring the pGEX-hGPI
plasmid was allowed to proliferate at 37°C, before 0.1 mM iso-
propyl-β-D-thiogalactopyranoside was added to the medium,
followed by further culture overnight at 30°C. The bacteria
were lysed with a sonicator and the supernatant was purified
with a glutathione-sepharose column (Pharmacia, Uppsala,
Sweden). The purity was estimated by SDS-PAGE.
Crude peptides were synthesised for epitope screening by
Mimotopes (Melbourne, Victoria, Australia), and peptides with
90% purity were synthesised for a major epitope decision and
induction of arthritis by Invitrogen (Carlsbad, CA). Candidate
peptides, which were thought to bind the binding motif, were
selected with web soft MHCPred (The Jenner Institute,
Oxford, UK) [7].
Induction of arthritis
DBA/1 mice were immunised with 300 μg rhGPI for GPI-
induced arthritis, or 10 μg or 25 μg synthetic peptide for pep-
tide-induced arthritis in complete Freund's adjuvant (Difco
Laboratories, Detroit, MI). The rhGPI and synthetic peptide
were emulsified with complete Freund's adjuvant at a 1:1 ratio
(v/v). For induction of arthritis, 150 μl of the emulsion was
injected intradermally at the base of the tail of the mouse. On
days 0 and 2 after immunisation, 200 ng of pertussis toxin was
injected intraperitoneally to develop peptide-induced arthritis.
The arthritis score was evaluated visually using a score of 0 to
3 for each paw. A score of 0 represented no evidence of
inflammation, 1 represented subtle inflammation or localised
oedema, 2 represented easily identified swelling but localised
to either the dorsal or ventral surface of the paws, and 3 rep-
resented swelling in all areas of the paws.
Treatments of arthritis with anti-IL-17 monoclonal 
antibodies
To neutralise IL-17, mice were injected intraperitoneally with
100 μg of neutralising antibody or isotype control on day 7 or
day 6, 8, and 10. Anti-IL-17 mAb MAB421 (IgG2a) was pur-
chased from R&D Systems (Minneapolis, MN, USA). IgG2a
isotype control was purchased from eBioscience (San Diego,
CA, USA).
Analysis of cytokine production
Mice were sacrificed on the indicated day. Spleens were har-
vested and haemolysed with a solution of 0.83% NH4Cl,
0.12% NaHCO3 and 0.004% EDTA2Na in PBS. Single-cell
suspensions were prepared in RPMI1640 medium (Sigma-
Aldrich, St. Louis, MO) containing 10% FCS, 100 U/ml of pen-
icillin, 100 μg/ml of streptomycin and 50 μM 2-mercaptoetha-
nol. CD4+ T cells were isolated by MACS positive selection
(Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of
the collected cells (>97%) was confirmed by flow cytometry.
Splenic feeder cells treated with 50 μg/ml of mitomycin C
were used as antigen presenting cells (APCs). The purified
CD4+ T cells and APCs were co-cultured with 10 μM of the
synthetic peptide at a ratio of 5:1 at 37°C under 5% CO2 for
24 hours. The supernatants were assayed for interferon (IFN)-
γ and IL-17 by Quantikine ELISA kit (R&D Systems, Minneap-
olis, MN).
Intracellular cytokine staining and flow cytometric 
analysis
Mice were sacrificed on day 5. The draining lymph nodes were
harvested and single cell suspensions were prepared as
described above. Cells (1×106/ml) were stimulated with 10
μM of the synthetic peptides in 96-well round bottom plates
(Nunc, Roskilde, Denmark) for 24 hours and GoldiStop (BD
PharMingen, San Diego, CA) was added for the last four hours
of each culture. Cells were first stained extracellularly, fixed
and permeabilised with Cytofix/Cytoperm solution (BD
PharMingen, San Diego, CA) and then stained intracellularly.Available online http://arthritis-research.com/content/10/6/R130
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Samples were acquired on FACSCalibur (BD PharMingen,
San Diego, CA) and data were analysed with FlowJo (Tree
Star, Ashland, OR).
Analysis of anti-GPI antibody
Sera were taken from immunised mice on day 14 and diluted
1:500 in blocking solution (25% Block Ace (Dainippon Sumi-
tomo Pharma, Osaka, Japan) in PBS) for antibody analysis.
We also prepared 96-well plates (Sumitomo Bakelite, Tokyo,
Japan) coated with 5 μg/ml rhGPI or recombinant mouse GPI
for 12 hours at 4°C. After washing twice with a washing buffer
(0.05% Tween20 in PBS), the blocking solution was used for
blocking nonspecific binding for two hours at room tempera-
ture. After three washes, 150 μl of the diluted serum was
added and incubated for two hoursat room temperature. After
three washes, alkaline phosphatase-conjugated anti-mouse
IgG was added at a final dilution of 1:5000, for one hour at
room temperature. After three washes, colour was developed
with substrate solution (1 alkaline phosphatase tablet (Sigma-
Aldrich, St. Louis, MO, USA) per 5 ml alkaline phosphatase
reaction solution (containing 9.6% diethanolamine and 0.25
mM MgCl2, pH 9.8)). Plates were incubated for 20 minutes at
room temperature and optical density was measured by a
microplate reader at 405 nm.
Immunohistology
For immunohistology, cryostat sections from ankle joints were
prepared with the tape capture technique as described previ-
ously [8]. Briefly, ankle joints were taken from immunised mice
on day 14 and placed in Tissue-Tek (Sakura Finetek, Torrance,
CA) filled with 4% carboxymethyl cellulose compound (Fine-
tec, Tokyo, Japan). Frozen ankles joints in the carboxymethyl
cellulose compound were attached to the adhesive Cryofilm
(Finetec, Tokyo, Japan) and were cut in the microtome. The
sections on the adhesive film were fixed with cold acetone.
After blocking with 2% bovine serum albumin and 0.05%
Tween in PBS, the sections were stained with Alexa 546-con-
jugated anti-mouse IgG (Invitrogen, Carlsbad, CA) (200 ng/
slide), and nuclei were counterstained with 4',6-diamidino-2-
phenyindole dilactate (DAPI) (Sigma-Aldrich, St. Louis, MO,
USA) (50 ng/slide). Fluorescence was detected with the Leica
DMRA2 microscopy (Leica, Wetzlar, Germany). The images
were acquired and processed with Leica FW4000 (Leica,
Wetzlar, Germany).
Statistical analysis
All data were expressed as mean ± standard error of the mean
(SEM) or standard deviation (SD). Differences between
groups and variables were examined for statistical significance
using the Mann-Whitney's U test and the Spearman's rank cor-
relation coefficient, respectively. A p < 0.05 denoted the pres-
ence of a statistically significant difference.
Results
I-Aq binding motif and epitope candidates
To analyse T cell epitopes, we first investigated the binding
motif of I-Aq from T cell epitopes reported in the literature
because DBA/1 mice express only I-Aq as MHC class II.
Based on the work by Bayrak and colleagues [9], the anchor
motif of I-Aq would exist at P1, P4 and P7, therefore we pre-
dicted the binding motifs from amino acid sequences of I-Aq
restricted epitopes on murine RNase90–105 [10], myelin basic
protein89–101 [11,12], chicken type II collagen (CII)181–209 [13],
rat CII256–270 [14,15], bovine CII256–270 [4] and mouse type II
collagen [9] (Table 1). Next, we selected 32 types of peptides
as core sequences from the human GPI 558 amino acid
sequence, which is thought to bind the binding motif (Table 2),
and synthesised 25 kinds of 20-mer peptides for screening,
each containing the core sequence in its centre (Table 3).
Epitope screening
rhGPI-specific CD4+ T cells differentiate into Th1 and Th17
[2], so we analysed IFN-γ and IL-17 production for epitope
screening when rhGPI-primed CD4+ T cells were stimulated
with each synthetic peptide. The production of both IFN-γ and
IL-17 was pronounced when GPI-primed CD4+ T cells were
stimulated with number 18 peptide (hGPI327–346) and number
25 peptide (hGPI539–558). Therefore, we considered that major
epitopes exist in either of the two peptides (Figure 1). In the K/
BxN mouse model of arthritis, KRN T cell receptor (TCR) trans-
genic T cells recognise mGPI282–294, the dominant epitope of
K/BxN mouse, on I-Ag7 [16]. However, in the GPI-induced
arthritis model, it was unlikely that hGPI282–294 was the domi-
nant epitope because GPI-specific T cells did not react prom-
inently to number 16 peptide (hGPI280–299).
Because the synthetic peptides used for screening were not
purified, we re-synthesised the 15-mer peptides with a purity
of 90%; these peptides contained each core sequence of
Table 1
I-Aq binding motifs
P1 P2 P3 P4 P5 P6 P7 P8 P9
AAE
FPD
LFQ
IS P
PVN
SLI
VN
R
The anchor motif of I-Aq would exist at P1, P4 and P7, therefore we 
predicted the binding motif from amino acid sequences of I-Aq 
restricted epitopes on murine RNase90–105, myelin basic 
protein89–101, chicken type II collagen181–209, rat type II 
collagen256–270, bovine type II collagen256–270 and mouse type II 
collagen.Arthritis Research & Therapy    Vol 10 No 6    Iwanami et al.
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number 18 peptide (hGPI327–346) and number 25 peptide
(hGPI539–558). Number 18 peptide (hGPI327–346) contains two
core sequences (hGPI328–336 and hGPI337–345), so therefore
we re-synthesised two peptides (hGPI325–339  and
hGPI334–348). The former sequences of number 25 peptide
(hGPI539–558) overlapped with number 24 peptide
(hGPI533–552), which could not stimulate CD4+ T cells primed
with GPI. Therefore we re-synthesised two peptides
(hGPI542–556 and hGPI544–558) from the latter sequences of
number 25 peptide (Table 4). We analysed IFN-γ and IL-17
production for epitope screening as described above. The
peptide (hGPI325–339) induced marked stimulation of GPI-
primed CD4+ T cells, and was considered a major epitope
(Figure 2).
Immunisation with a major epitope induces arthritis 
similar to GPI-induced arthritis
To test if hGPI325–339 is arthritogenic, DBA/1 mice were immu-
nised with 10 μg or 25 μg hGPI325–339 instead of GPI protein,
and 200 ng of pertussis toxin was injected intraperitoneally on
days 0 and 2 after immunisation. Arthritis resembling GPI-
induced arthritis could be generated by immunisation with the
peptide, including incidence, manifestations and severity.
Symmetrical polyarthritis appeared on day 8, showed peak
severity on day 14 and subsided gradually thereafter (Figure
3a). The use of different immunisation doses (10 and 25 μg)
did not seem to affect the incidence and severity of arthritis.
Immunised with 10 μg or 25 μg hGPI325–339 without injection
of pertussis toxin could also induce arthritis. However, the
arthritis was less severe than with pertussis toxin (data not
shown). On the other hand, immunisation with neither
hGPI539–558 nor hGPI544–558, which were considered minor
epitopes in GPI-induced arthritis, could induce overt arthritis
(Figure 3a). Mice immunised with hGPI325–339  developed
severe swelling of the wrist and ankle joints. Histologically,
severe synovitis was noted in the wrists in the forepaws, and
at ankles and tarsal joints in the hind paws (Figure 3b and data
not shown).
Peptide-induced arthritis is mediated by Th17
GPI-induced arthritis is Th17-mediated [2], so we explored the
aetiological role of Th17 in peptide-induced arthritis. Like GPI-
induced arthritis, one time administration of anti-IL-17 mAb on
day 7 and three times administration on day 6, 8 and 10 sig-
nificantly ameliorated the arthritis (Figure 4). From these data,
the arthritis induced by hGPI325–339 was also considered to be
Th17 mediated.
Immunisation of human GPI325–339 leads Th17 cells to 
cross-react with mouse GPI325–339
We examined the pathogenesis of arthritis induced by
hGPI325–339  by comparing it with mice immunised with
hGPI544–558.
First, we speculated that the difference in cross-reactivity to
mouse GPI might affect the incidence of arthritis, because
hGPI325–339 (IWYINCFGCETHAML) has 13/15 amino acids
homology to mGPI325–339  (IWYINCYGCETHALL) while
hGPI544–558  (GLINFIKQQREARVQ) has only 9/15 amino
Table 2
Core sequences of glucose-6-phosphate isomerase (GPI) 
amino acids binding I-Aq
Peptide Amino acid residues
3–11 ALTRDPQFQ
29–37 LFDANKDRF
41–49 SLTLNTNHG
56–64 SKNLVTEDV
72–80 AKSRGVEAA
80–88 ARERMFNGE
99–107 LHVALRNRS
102–110 ALRNRSNTP
149–157 ITDVINIGI
167–175 VTEALKPYS
173–181 PYSSGGPRV
181–189 VWYVSNIDG
196–204 LAQLNPESS
201–209 PESSLFIIA
210–218 SKTFTTQET
229–237 FLQAAKDPS
230–238 LQAAKDPSA
243–251 FVALSTNTT
253–261 VKEFGIDPQ
285–293 ALHVGFDNF
319–327 LLALLGIWY
328–336 INCFGCETH
337–345 AMLPYDQYL
391–399 FYQLIHQGT
403–411 PCDFLIPVQ
407–415 LIPVQTQHP
426–434 LANFLAQTE
452–460 AGKSPEDLE
489–497 ALVAMYEHK
537–545 SHDASTNGL
540–548 ASTNGLINF
545–553 LINFIKQQR
Thirty-two types of peptides were selected as core sequences from 
the GPI 558 amino acid sequence, which is thought to bind the 
binding motif. Amino acid residues that are thought to bind anchors 
of I-Aq are shown in bold letters.Available online http://arthritis-research.com/content/10/6/R130
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acids homology to mGPI544–558 (GLISFIKQQRDTKLE). The
draining lymph node cells from mice immunised with
hGPI325–339 or hGPI544–558were cultured in the presence of
hGPI325–339, mGPI325–339, hGPI544–558 or mGPI544–558 for 24
hours. The hGPI325–339-primed cells had distinct cross-reac-
tive immune reaction to mGPI325–339  by producing IL-17,
whereas the hGPI544–558 primed cells did not cross-react to
mGPI544–558 (Figure 5a). As compared with the draining lymph
node cells of hGPI325–339-immunised mice, IL-17 production
was not remarkable in that of hGPI544–558-immunised mice
even when the corresponding peptide was used as an antigen
for in vitro stimulation (Figure 5a). The production of IFN-γ was
much lower than that of IL-17, and IL-4 production was not
detectable independent of immunisation patterns and anti-
gens for in vitro stimulation (data not shown).
It has been reported that Th17 cells are not the only cellular
sources of IL-17, but CD8+ T cells, natural killer T cells and γδT
cells are also capable of producing IL-17 [17-22]. Therefore,
we investigated the IL-17 producing cells using flow cytome-
try. The draining lymph node cells from mice immunised with
hGPI325–339 or hGPI544–558 were stimulated with hGPI325–339
and mGPI325–339, or hGPI544–558 and mGPI544–558, respec-
tively. Intracellular cytokine staining was performed without
nonspecific stimulants, such as phorbol myristate acetate or
ionomycin. We confirmed that immunisation of hGPI325–339
induced antigen-specific Th17 cells, which cross-reacted with
mGPI325–339. However, immunisation of hGPI544–558 induced
neither hGPI544–558-specific Th17 cells nor Th17 cells that can
cross-react with mGPI544–558 remarkably (Figure 5b). These
data indicate that induction of antigen-specific Th17 cells and
Table 3
Synthetic peptides for screening T cell epitopes
Peptide number Peptide Synthetic peptide sequence
1 1–20 H-MAALTRDPQFQKLQQWYREH-OH
2 23–42 H-ELNLRRLFDANKDRFNHFSL-OH
3 37–56 H-FNHFSLTLNTNHGHILVDYS-OH
4 51–70 H-ILVDYSKNLVTEDVMRMLVD-OH
5 71–90 H-LAKSRGVEAARERMFNGEKI-OH
6 96–115 H-RAVLHVALRNRSNTPILVDG-OH
7 145–164 H-TGKTITDVINIGIGGSDLGP-OH
8 162–181 H-LGPLMVTEALKPYSSGGPRV-OH
9 168–187 H-TEALKPYSSGGPRVWYVSNI-OH
10 176–195 H-SGGPRVWYVSNIDGTHIAKT-OH
11 191–210 H-HIAKTLAQLNPESSLFIIAS-OH
12 200–219 H-NPESSLFIIASKTFTTQETI-OH
13 225–244 H-AKEWFLQAAKDPSAVAKHFV-OH
14 238–257 H-AVAKHFVALSTNTTKVKEFG-OH
15 247–266 H-STNTTKVKEFGIDPQNMFEF-OH
16 280–299 H-IGLSIALHVGFDNFEQLLSG-OH
17 313–332 H-EKNAPVLLALLGIWYINCFG-OH
18 327–346 H-YINCFGCETHAMLPYDQYLH-OH
19 386–405 H-NGQHAFYQLIHQGTKMIPCD-OH
20 400–419 H-KMIPCDFLIPVQTQHPIRKG-OH
21 420–439 H-LHHKILLANFLAQTEALMRG-OH
22 445–464 H-ARKELQAAGKSPEDLERLLP-OH
23 484–503 H-PFMLGALVAMYEHKIFVQGI-OH
24 533–552 H-AQVTSHDASTNGLINFIKQQ-OH
25 539–558 H-DASTNGLINFIKQQREARVQ-OH
Listed are 25 20-mer unpurified peptides in which each core sequence were centred around. Amino acid residues constituting the core sequence 
and those thought to bind anchors of I-Aq are underlined and shown in bold letters, respectively.Arthritis Research & Therapy    Vol 10 No 6    Iwanami et al.
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cross-reactivity with mouse GPI might be the pathogenesis of
peptide-induced arthritis.
Immunisation of human GPI325–339 leads B cells to 
produce anti-mouse GPI antibodies
To explore the importance of autoantibodies, we measured
anti-human GPI antibodies and anti-mouse GPI antibodies in
mice immunised with hGPI325–339, hGPI544–558  and
hGPI325–339 plus hGPI544–558by ELISA. Mice immunised with
rhGPI and the two peptides (hGPI325–339 plus hGPI544–558)
produced high titres of anti-human GPI antibodies and anti-
mouse GPI antibodies, and mice immunised with hGPI325–339
and hGPI544–558 hardly produced any anti-human GPI antibod-
ies. However, mice immunised with hGPI325–339 produced sig-
nificantly higher titres of anti-mouse GPI antibodies than mice
immunised with hGPI544–558 (Figure 6a). It is noteworthy that
immunisation with the two peptides (hGPI325–339  plus
hGPI544–558) induced significantly higher titres of anti-mouse
GPI antibodies than that with hGPI325–339 alone, whereas the
severity and incidence of arthritis in mice immunised with two
peptides (hGPI325–339  plus hGPI544–558) were comparable
with those in mice immunised with hGPI325–339 alone (Figures
3a and 6a).
Figure 1
Synthetic peptides number 18 and 25 produced marked simulation of  glucose-6-phosphate isomerase (GPI) primed CD4+ T cells Synthetic peptides number 18 and 25 produced marked simula-
tion of glucose-6-phosphate isomerase (GPI) primed CD4+ T cells. 
Mice were sacrificed on day 7 after immunisation. CD4+ T cells were 
purified from spleen cells of GPI-immunised DBA/1 mice. GPI-primed 
CD4+ T cells and antigen presenting cells (APCs) were co-cultured 
with 10 μM of synthetic peptide for 24 hours. The supernatants were 
assayed for interferon (IFN) γ and interleukin (IL) 17 by ELISA. Data are 
averages ± standard deviation of three culture wells. Representative 
data of three independent experiments.
Figure 2
GPI325–339 is a major epitope GPI325–339 is a major epitope. Mice were sacrificed on day 7 after 
immunisation. CD4+ T cells were purified from splenocytes of glucose-
6-phosphate isomerase (GPI) immunised DBA/1 mice. GPI-primed 
CD4+ T cells and antigen presenting cells (APCs) were co-cultured 
with 10 μM of synthetic peptide hGPI325–339, hGPI334–348, hGPI542–556 
or hGPI544–558 for 24 hours. The purity of each peptide was 90%. The 
supernatants were assayed for interferon (IFN) γ and interleukin (IL) 17 
by ELISA. Data are averages ± standard deviation of five culture-wells. 
**p < 0.01 (Mann-Whitney's U test). Representative data of three inde-
pendent experiments.Available online http://arthritis-research.com/content/10/6/R130
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We further investigated the difference of the correlation
between anti-mouse GPI antibodies and arthritis score among
immunisation patterns. Each of the three different immunisa-
tion patterns (rhGPI, hGPI325–339  and hGPI325–339  plus
hGPI544–558) showed no positive correlation between anti-
mouse GPI antibodies and arthritis score (Table 5).
Next, we investigated the existence of IgG on the cartilage sur-
face by immunohistology, because GPI were proved to
deposit on the cartilage surface of normal naïve mice [23]. The
cryostat sections of ankle joints from naïve mice and mice
immunised with hGPI544–558 did not show IgG deposit on the
cartilage surface. However, those from mice immunised with
rhGPI and hGPI325–339 showed IgG deposits (Figure 6b).
These data indicate that anti-mouse GPI antibodies may play
a role in the development of peptide-induced arthritis.
Discussion
GPI, a ubiquitous glycolytic enzyme, is a new autoantigen can-
didate in autoimmune arthritis [5,6]. GPI-induced arthritis is
induced by immunisation of genetically unaltered DBA/1 mice
with rhGPI [1]. We report here the therapeutic efficacies of
mAb to tumour necrosis factor-α and IL-6 and CTLA-4 Ig in
this model [3]. Moreover, CD4+ T cells, especially Th17 cells,
seem to be more important than B cells, because administra-
tion of anti-CD4 mAb or anti-IL-17 mAb markedly ameliorate
the progress of arthritis independent of anti-GPI antibodies
titres [1,2]. Therefore, exploring the epitope of CD4+ T cells
and its arthritogenic effect is important for understanding the
pathological mechanisms.
In this study, we investigated the binding motif of I-Aq from T
cell epitopes considered to bind to I-Aq, synthesised peptides
of epitope candidates and identified hGPI325–339 as a major
epitope. Interestingly, the MHC binding residues of
hGPI325–339(IWYINCFGCETHAML) at P1, P4 and P7 were
the same as those for bovine CII256–270  (GEP-
induced arthritis [4]. These findings indicate that the binding
motif (P1 I, P4 F, P7 E) might have high binding affinity with I-
Aq, and the peptides with this motif-MHC complexes might be
effectively recognised by TCRs and could be arthritogenic in
some condition. Although immunisation with a fragment of
Table 4
Re-synthesised peptides used for determining a major epitope
Peptide number Peptide Synthetic peptide sequence
18 327–346 H-YINCFGCETHAMLPYDQYLH-OH
325–339 H-IWYINCFGCETHAML-OH
334–348 H-ETHAMLPYDQYLHRF-OH
25 539–558 H-DASTNGLINFIKQQREARVQ-OH
542–556 H-TNGLINFIKQQREAR-OH
544–558    H-GLINFIKQQREARVQ-OH
The 15-mer peptides were synthesised with 90% purity, containing 
each core sequence of number 18 peptide (GPI327–346) and number 
25 peptide (GPI539–558). Amino acid residues constituting the core 
sequence and those thought to bind the anchors of I-Aq are 
underlined and shown in bold letters, respectively.
Figure 3
Immunisation with hGPI325–339 induces severe polyarthritis Immunisation with hGPI325–339 induces severe polyarthritis. DBA/1 
mice were immunised with 25 μg of hGPI325–339, hGPI539–558 or 
hGPI544–558, or 10 μg each of hGPI325–339 plus hGPI544–558, and 200 
ng of pertussis toxin was injected intraperitoneally on days 0 and 2 after 
immunisation. (a) The mean arthritis score (± standard error of the 
mean (SEM)) of five mice in one representative experiment of two inde-
pendent experiments. (b) Severe swelling of the wrist (upper panels) 
and ankle joints (middle panels) in mice immunised with 25 μg of 
hGPI325–339 compared with naïve mice (arrowheads). Histological anal-
ysis of haematoxylin & eosin-stained sections of ankle joints taken from 
naïve mice and mice on day 14 after hGPI325–339 immunization (lower 
panels) showed severe synovitis with massive infiltration of cells and 
hyperplasia of synovial tissue (arrowheads).Arthritis Research & Therapy    Vol 10 No 6    Iwanami et al.
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cyanogen bromide of bovine CII, CB11 (CII124–402), which
contains the dominant epitope, can induce arthritis, the sever-
ity and incidence are much lower than arthritis induced by
bovine CII protein [4]. Other fragments (CB8, CB9, CB10 and
CB12) do not induce arthritis, as is explained by the produc-
tion of anti-bovine CII antibodies. Immunisation with CB11
fragment produces five times more antibodies to bovine CII
than any other fragment [4]. The observation that administra-
tion of anti-CD4 mAb after the onset of arthritis did not amel-
iorate the arthritis [24,25] and a combination of mAb to CII can
passively transfer arthritis to naïve mice [26] also emphasises
the importance of autoantibodies to the induction of collagen-
induced arthritis.
Our study demonstrated that immunisation with hGPI325–339
induced antigen-specific Th17 cells, which can cross-react
with mGPI325–339 and lead B cells to produce anti-mouse GPI
antibodies. However, immunisation with hGPI544–558 could not
even induce hGPI544–558-specific Th17 cells. The difference of
ability of Th17 induction between two peptides may come
from MHC-binding affinity and TCR-binding affinity. A peptide
that is likely to bind to MHC class II with high affinity and inter-
acts strongly with the T cell receptor tends to stimulate Th1-
cell response, whereas a peptide with low binding affinity to
MHC class II and T cell receptor tends to elicit Th2-cell
response [27,28]. Although the relationship between Th17
differentiation and the strength of TCR signalling and MHC-
binding affinity has not been clarified, it is possible that the dif-
ference in amino acid sequences between hGPI325–339 and
hGPI544–558 might affect the I-Aq binding affinity and the TCR
signalling, and consequently lead to the difference in extent of
antigen-specific Th17 cells. In this study, we did not detect
any IL-4 production, which is an adjuvant effect of Mycobac-
terim tuberculosis and pertussis toxin.
In K/BxN mice expressing I-Ag7 as MHC class II molecules,
mGPI282–294-specific CD4+ T cells lead B cells to produce
anti-mouse GPI antibodies [16]. The anti-mouse GPI antibod-
ies from K/BxN mice have such high affinity that IgG transfer
of K/BxN mice can provoke arthritis in normal mice [6]. In com-
parison, the anti-mouse GPI antibodies from GPI-induced
arthritis alone are not sufficient for the development of arthritis
because IgG transfer from mice immunised with rhGPI can not
provoke arthritis. However, IgG signalling through FcγR seems
necessary for the induction of GPI-induced arthritis because
FcγR-deficient mice are resistant to arthritis [1]. Moreover, the
data that transfer of rhGPI-primed or hGPI325–339-primed Th17
cells to naïve DBA/1 mice can not induce arthritis emphasises
the necessity of anti-mouse GPI antibodies (unpublished
observation). Considering the data that there are no positive
correlation between anti-mouse GPI antibodies and arthritis
score [[29] and unpublished observation], and arthritis-resist-
ant mice like C57BL/6 produce as high titres of anti-mouse
GPI antibodies as DBA/1 when immunised with rhGPI (1 and
unpublished observation), anti-mouse GPI antibodies may play
a subordinate role in the development of GPI-induced arthritis
and peptide-induced arthritis in DBA/1 mice.
In the process of epitope screening, the response to
hGPI539–558 peptide was comparable with that to hGPI327–346
peptide; however, the response to hGPI542–556  and
hGPI544–558, which were synthesised with 90% purity, was
lower than that to hGPI539–558  peptide. Furthermore, the
response to hGPI539–558, which was re-synthesised with 90%
purity, was much lower than to hGPI325–339 or to hGPI539–558
peptide for screening (data not shown). These results could
be explained by differences in the purity of the synthetic pep-
tides. The synthetic peptides used for screening (peptides
numbers 1 to 25, Table 2) were unpurified, and the purity of
each peptide would have been quite different, although the
exact purity was unchecked by the product maker. Therefore,
it is possible that the purity of number 25 peptide might have
been much higher than that of number 18 peptide, or alterna-
tively, number 25 peptide may have contained other peptides
through peptide synthesis.
From a probability point of view, it is possible that other
epitopes exist in some regions of human GPI-amino acid
Figure 4
Anti-IL-17 monoclonal antibody (mAb) suppresses the development of  arthritis Anti-IL-17 monoclonal antibody (mAb) suppresses the develop-
ment of arthritis. DBA/1 mice were immunised with 25 μg of 
hGPI325–339, and 200 ng of pertussis toxin was injected intraperito-
neally on days 0 and 2 after immunisation. 100 μg of anti-IL-17 mAb or 
isotype control (control) was administered intraperitoneally on day 7 
(upper panel) or day 6, 8, and 10 (lower panel) after immunisation 
(arrow). Mean arthritis score (± standard error of the mean (SEM)) of 
five mice per group. Representative data of two independent experi-
ments. * p < 0.05, ¶p < 0.01 (Mann-Whitney's U test).Available online http://arthritis-research.com/content/10/6/R130
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Figure 5
Cross-reactivity with peptides derived from mouse glucose-6-phosphate isomerase (GPI) Cross-reactivity with peptides derived from mouse glucose-6-phosphate isomerase (GPI). (a) Draining lymph node (DLN) cells taken from 
hGPI325–339-immunised mice on day 5 were cultured with 10 μM of hGPI325–339, mGPI325–339, hGPI544–558 or mGPI544–558 for 24 hours. The super-
natants were assayed for interleukin (IL) 17 by ELISA. Data are averages ± standard deviation of three culture-wells. Representative data of three 
independent experiments. (b) DLN cells taken from hGPI325–339- or hGPI544–558-immunised mice on day 5 were cultured with 10 μM of hGPI325–339 
and mGPI325–339 or hGPI544–558 and mGPI544–558, respectively. GoldiStop was added at the last four hours of each culture. Flow cytometry for IL-17 
and interferon (IFN) γ was gated in CD3+, CD4high cells. Representative flow cytometry data of three independent experiments with two mice per 
experiment.Arthritis Research & Therapy    Vol 10 No 6    Iwanami et al.
Page 10 of 12
(page number not for citation purposes)
sequence from which we did not synthesise the peptides,
because I-Aq may have another binding motif and our synthe-
sised peptides covered only the 399/558 (71.5%) amino acid
residues of human GPI protein, not the whole length. How-
ever, two experimental pieces of data support that hGPI325–339
may be the dominant epitope. One is that immunisation with
hGPI325–339 provoked arthritis similar to that induced by rhGPI
protein. The other is that intraperitoneal injection of
hGPI325–339 after the onset of arthritis significantly ameliorated
the progress of arthritis (data not shown). Because systemic
Figure 6
Titres of anti-mouse glucose-6-phosphate isomerase (GPI) antibodies were elevated in mice with arthritis Titres of anti-mouse glucose-6-phosphate isomerase (GPI) antibodies were elevated in mice with arthritis. (a) Sera were taken on day 14 
from mice immunised with recombinant human (rh) GPI, hGPI325–339, hGPI544–558 or hGPI325–339 plus hGPI544–558, and the titres of anti-human GPI 
antibodies and anti-mouse GPI antibodies were analysed by ELISA. Each symbol represents a single mouse. Data are mean optimal density ± stand-
ard deviation. †p < 0.01 (Mann-Whitney's U test). Representative data of two independent experiments. (b) Ankle joints were taken on day 14 from 
mice immunised with rhGPI, hGPI325–339 or hGPI544–558. Cryostat sections of ankle joints were stained with anti-mouse IgG (red), and nuclei were 
counterstained with 4',6-diamidino-2-phenyindole dilactate (blue). Representative data of three independent experiments.Available online http://arthritis-research.com/content/10/6/R130
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administration of a dominant epitope leads to anergy of patho-
genic T cells or results in activation-induced cell death
[30,31], this inhibitory effect of hGPI325–339 on GPI-induced
arthritis supports the notion that hGPI325–339 may be the dom-
inant epitope.
Cross-reactivity is considered the one of mechanisms of
autoimmune diseases. We previously identified patients with
RA who have GPI-reactive CD4+ T cells and found that some
of them express human leucocyte antigen-DR4 as MHC class
II [32]. Because the I-Aq binding motif resembles DR4 [9], fur-
ther studies are needed to define epitopes of CD4+ T cells in
such patients and search proteins that have homology to the
epitopes.
Conclusions
This study is the first report of experimental arthritis induced by
immunisation with a single short peptide in genetically unal-
tered mice. The fact that an immunological reaction to a single
short peptide of ubiquitously expressed protein causes polyar-
thritis provides new insight to the understanding of autoim-
mune arthritis.
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